TrialAdvances in therapy2024

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.

Ana Oaknin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.